Table 3.

Median (5–95th percentiles) hormone concentrations in case patients and control subjects not using oral contraceptives^*

	Case patients (n = 98)		Control subjects (n = 169)
	Median	5–95th percentiles	Median	5–95th percentiles	P†
Müllerian inhibiting substance, ng/mL	0.30	0.03–3.4	0.10	0.03–2.5	<.001
Estradiol, pg/mL	92.5	23.0–277.0	98.0	12.0–248.0	.97
Bioavailable estradiol, pg/mL	56.5	12.2–153.2	54.8	8.6–146.1	.84
Testosterone, ng/dL	27.5	16.0–49.6	25.7	13.0–44.3	.01
Bioavailable testosterone, ng/dL	11.7	5.7–23.5	10.2	4.9–19.0	.004
SHBG, nmol/L	57.5	27.3–114.0	60.7	26.1–117.0	.24

^*Case patients and control subjects from matched sets where the case patient and at least one control subject were not using oral contraceptives at blood collection in the prospective case–control study of serum Müllerian inhibiting substance and breast cancer risk nested in the Columbia, Missouri Serum Bank. All variables are continuous. SHBG = sex hormone–binding globulin.

^†P values (two-sided) were calculated by using conditional logistic regression with quartile ranks entered as a linear term to test for trend using a Wald test.